Quanterix (NASDAQ: QTRX) is a life sciences company specializing in the development and commercialization of ultra-sensitive diagnostic and research platforms. Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix pioneered the Single Molecule Array (Simoa) technology to enable the detection of proteins, nucleic acids and other biomarkers at concentrations previously undetectable by conventional methods.
The company’s flagship products include the Simoa HD-X Analyzer and the SP-X System, which leverage digital immunoassay and microarray technologies, respectively, to deliver high-throughput, precision results. Quanterix offers an expanding menu of assay kits, consumables and software, supporting applications in neuroscience, oncology, cardiology, infectious diseases and other research areas. These platforms are designed for both research use and translational applications, facilitating biomarker discovery, drug development and personalized medicine efforts.
Quanterix serves a global customer base, including pharmaceutical and biotech companies, academic research centers, contract research organizations and clinical laboratories. The company has established commercial operations and partnerships across North America, Europe and the Asia-Pacific region, providing instrument deployment, training and technical support to ensure seamless integration of its systems into diverse laboratory workflows.
Under the leadership of President and Chief Executive Officer Kevin Hrusovsky, Quanterix continues to expand its offerings through ongoing R&D investments and strategic collaborations. The company’s management team, including Chief Financial Officer Catherine Burzik and other seasoned life-sciences executives, is focused on driving innovation while maintaining robust operational and quality standards. Quanterix remains committed to advancing biomarker science and accelerating the translation of critical research into tangible clinical insights.
AI Generated. May Contain Errors.
